$MNK (Mallinckrodt Public Limited Company)

$MNK {{ '2015-08-04T12:22:13+0000' | timeago}} • Announcement

$MNK 3Q15 PR: Net sales were $965.1MM compared with $653.1MM in 3Q14, an increase of 47.8%. On a GAAP basis, net income for 3Q15 was $58MM compared with a net loss of $24.1MM in the prior-year period. The increase in net income principally reflects increased net sales and profits in the Specialty Brands segment from acquisitions.

$MNK {{ '2017-12-26T12:28:16+0000' | timeago}} • Announcement

$MNK agreed to buy $SCMP, including its commercial and development assets, for about $1.2Bil. $MNK's subsidiary Sun Acquisition Co. will begin a cash tender offer for $18 per share. $MNK expects accretion from acquisition to adjusted EPS of at least $0.30 in 2018 and at least double that amount in 2019, assuming 1Q18 close.

$IVC {{ '2017-08-21T13:49:14+0000' | timeago}} • Announcement

$IVC, provider of non-acute medical equipment, has appointed Barbara Bodem to its BoD, effective Aug 18, 2017. She is the SVP of Finance of $MNK since Oct, 2015. Her appointment brings the number of Directors to eight, seven of whom are independent Directors.

$MNK {{ '2017-08-08T14:11:21+0000' | timeago}} • Infographic

$MNK Mallinckrodt Earnings AlphaGraphic: Q2 2017 highlights

$MNK {{ '2017-06-23T12:00:49+0000' | timeago}} • Announcement

$MNK announced new retrospective, claims-based health economic data that show rare, life-threatening disease hepatorenal syndrome (HRS), or the development of renal (kidney) failure in patients with advanced chronic liver disease, imposes a significant economic burden on payers.

$MNK {{ '2017-06-07T12:19:43+0000' | timeago}} • Announcement

$MNK has confirmed enrollment of the first patient in its phase-3 study on StrataGraft regenerative skin tissue, which mimics natural skin, in the promotion of autologous skin regeneration of complex skin defects due to thermal burns that contain intact dermal elements. The study will include patients with 3-49% complex skin defects due to burns.

$MNK {{ '2017-05-24T11:58:11+0000' | timeago}} • Announcement

$MNK confirmed  enrollment of the first patient in its Phase 4 pilot study assessing the efficacy of H.P. Acthar Gel (repository corticotropin injection) for multiple sclerosis relapse. H.P. Acthar Gel is U.S. Food and Drug Administration (FDA)-approved for treatment of acute exacerbations of multiple sclerosis in adults.

$MNK {{ '2017-05-19T21:17:00+0000' | timeago}} • Announcement

$MNK presented facts to refute short-seller claims. Recent media reports have cited allegations by self-acknowledged short sellers whose thesis on $MNK, the company believes, is not based on fact and is intentionally misleading. This statement serves to present facts and correct inaccuracies in those media reports.

$MNK {{ '2017-05-08T18:06:45+0000' | timeago}} • Webcast

$MNK expects SG&A costs to continue to be high into 2Q17, and then see some of that leverage as Mallinckrodt gets into the second half of the year. The company sees second quarter EPS to be more in line with that of 1Q17.

$MNK {{ '2017-05-08T17:49:38+0000' | timeago}} • Webcast

As Mallinckrodt posted its 1Q17 results, $MNK expects its business to expand as a proportion in the Specialty Brands arena in the long-term. The pharma company sees its Specialty Brands business likely growing faster in than the Generics segment.

$MNK {{ '2017-05-08T15:30:24+0000' | timeago}} • Infographic

$MNK Mallinckrodt plc Earnings AlphaGraphics: Q1 2017 highlights

$MNK {{ '2017-05-08T11:11:50+0000' | timeago}} • Announcement

$MNK, which changed its financial period after last quarter results, posted a 4.1% rise in its net sales for the Specialty Brands segment of $557MM in 1Q17. Specialty Generics segment net sales slumped 9.8% to $239MM. Mallinckrodt's cash balance was $260MM at the end of the quarter with its $900MM revolver undrawn.

$MNK {{ '2017-05-08T11:08:09+0000' | timeago}} • Announcement

Net sales of $MNK slipped 0.6% to $811MM in 1Q17, as the biopharma company's net income more than tripled to $399MM from last year's $118MM. Earnings jumped to $3.86 per diluted share from $1.06 a share, while diluted EPS from continuing operations slipped to $0.28 from $088. Income from continuing operations shrunk to $29MM from $99MM a year ago.

$MNK {{ '2017-04-03T13:37:45+0000' | timeago}} • Announcement

$MNK reached an agreement in principle with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys’ Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York. This is to resolve investigations into company monitoring programs for controlled substances. $MNK agreed to pay $35MM to settle past claims.

$MNK {{ '2017-03-20T12:15:38+0000' | timeago}} • Announcement

$MNK said it has closed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the U.K., Piramal Critical Care, for approx. $203MM. The transaction will consist of $171MM of fixed consideration of which 10% will be paid at closing, and an additional $154MM will be paid on the first anniversary of the close date.

$MNK {{ '2017-03-01T16:13:13+0000' | timeago}} • Announcement

$MNK said board and management long-term outlook reflected in share repurchase authorization, reinforces its inherent long-term earnings power and free cash generation capabilities. $MNK expects to apply range of capital deployment levers, including strategic, financially sound business development opportunities, and potentially debt reduction.

$MNK {{ '2017-03-01T16:09:13+0000' | timeago}} • Announcement

$MNK BoD authorized an incremental $1Bil repurchase of ordinary shares. The share repurchase program is open-ended in time. $MNK also elected 9 nominees to the BoD, which include Melvin Booth, David Carlucci, Martin Carroll, Diane Gulyas, JoAnn Reed, Angus Russell, Mark Trudeau, Kneeland Youngblood, and Joseph Zaccagnino.

$MNK {{ '2017-02-07T14:47:06+0000' | timeago}} • Webcast

$MNK said it plans to buy more shares during 2017, given the current share price, authorization and liquidity. The company, however, refused to give any specific quantitative levels. At the end of Dec., the company had just north of $260MM on its current authorization program.

$MNK {{ '2017-02-07T14:30:27+0000' | timeago}} • Webcast

For the transitional period, $MNK has published about 25 dataset across its portfolio. Out of the 25 data release, 12 were for Acthar. The company said it has been consistent with the type of volume of data it has generated for the past several quarters and expects that trend to continue in 2017.

$MNK {{ '2017-02-07T14:05:47+0000' | timeago}} • Webcast

During the transition period from Oct. 1, 2016 to Dec. 30, 2016, $MNK generated free cash flow of $130MM. The company said that YoY cash flow for 2017 will decrease due to divestiture and weakness in Specialty Generics.

$MNK {{ '2017-02-07T14:02:02+0000' | timeago}} • Webcast

$MNK expects to be very active with business development during 2017. The company said there are number of highly attractive assets that fits well within its strategic objectives, and it will continue to focus on finding the right assets at the right price.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, August 8 2017 - 12:30pm

AlphaGraphics you may like